

Daniel L Piskorz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6518476/publications.pdf>

Version: 2024-02-01

59
papers

23,942
citations

279487

23
h-index

205818

48
g-index

63
all docs

63
docs citations

63
times ranked

24495
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1119-1131.	13.9	6,227
2	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2013, 369, 2093-2104.	13.9	4,215
3	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	13.9	2,821
4	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2013, 369, 1327-1335.	13.9	2,261
5	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	13.9	2,143
6	Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. <i>Lancet, The</i> , 2006, 368, 1096-1105.	6.3	1,564
7	Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2012, 367, 2204-2213.	13.9	1,145
8	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 69.	3.8	830
9	Effect of Ramipril on the Incidence of Diabetes. <i>New England Journal of Medicine</i> , 2006, 355, 1551-1562.	13.9	684
10	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. <i>Lancet, The</i> , 2015, 385, 2067-2076.	6.3	659
11	Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. <i>Diabetes Care</i> , 2008, 31, 1007-1014.	4.3	160
12	Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. <i>Diabetologia</i> , 2004, 47, 1519-1527.	2.9	157
13	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	2.1	139
14	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <i>Circulation</i> , 2017, 135, 1273-1275.	1.6	133
15	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	1.6	127
16	Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. <i>Circulation</i> , 2019, 139, 351-361.	1.6	126
17	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. <i>Stroke</i> , 2016, 47, 2075-2082.	1.0	83
18	Frequency of Family History of Acute Myocardial Infarction in Patients With Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 1997, 80, 122-127.	0.7	81

#	ARTICLE	IF	CITATIONS
19	Guidelines on the management of arterial hypertension and related comorbidities in Latin America. <i>Journal of Hypertension</i> , 2017, 35, 1529-1545.	0.3	58
20	Cardioversion of Atrial Fibrillation in <sc>ENGAGE AFâ€TIMI</sc> 48. <i>Clinical Cardiology</i> , 2016, 39, 345-346.	0.7	53
21	Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin. <i>Stroke</i> , 2014, 45, 2372-2378.	1.0	46
22	Atherogenic Dyslipidemia in Latin America: Prevalence, causes and treatment. <i>International Journal of Cardiology</i> , 2017, 243, 516-522.	0.8	37
23	Hypertensive Mediated Organ Damage and Hypertension Management. How to Assess Beneficial Effects of Antihypertensive Treatments?. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 9-17.	1.0	25
24	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. <i>Hypertension</i> , 2016, 68, 606-613.	1.3	21
25	Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AFâ€TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	21
26	Position statement of the Interamerican Society of Cardiology (IASC) on the current guidelines for the prevention, diagnosis and treatment of arterial hypertension 2017â€2020. <i>International Journal of Cardiology: Hypertension</i> , 2020, 6, 100041.	2.2	19
27	Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation. <i>Current Problems in Cardiology</i> , 2017, 42, 198-225.	1.1	17
28	Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus document of the Inter-American Society of Cardiology and the World Heart Federation. <i>Global Heart</i> , 2021, 16, 55.	0.9	14
29	Psychological Impact of the Pandemic on Ambulatory Cardiometabolic Patients Without Evidence of SARS-CoV-2 Infection. The CorCOVID Latam Psy Study. <i>Current Problems in Cardiology</i> , 2021, 46, 100737.	1.1	10
30	Impact of the Pandemic on Noninfected Cardiometabolic Patients: A Survey in Countries of Latin Americaâ€Rationale and Design of the CorCOVID LATAM Study. <i>CJC Open</i> , 2020, 2, 671-677.	0.7	9
31	Ambulatory Patients with Cardiometabolic Disease and Without Evidence of COVID-19 During the Pandemic. The CorCOVID LATAM Study. <i>Global Heart</i> , 2021, 16, 15.	0.9	8
32	Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial. <i>Journal of Human Hypertension</i> , 2017, 31, 178-188.	1.0	7
33	Association of systolic dysfunction with left ventricular hypertrophy and diastolic dysfunction in hypertensive patients. <i>Revista De La Facultad De Ciencias Medicas De Cordoba</i> , 2014, 71, 158-64.	0.1	6
34	Functional Organ Damage in Cardiovascular Low Risk Patients with High Central Aortic Pressure. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 281-287.	1.0	5
35	Considerations and Guidance for the Structure, Organisation, and Operation of Cardiometabolic Prevention Units: A Consensus Statement of the Inter-American Society of Cardiology. <i>Global Heart</i> , 2021, 16, 27.	0.9	4
36	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). <i>Archivos De Cardiologia De Mexico</i> , 2021, 92, .	0.1	4

#	ARTICLE	IF	CITATIONS
37	Morphologic and Functional Heart Abnormalities Associated to High Modified Tei Index in Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 373-380.	1.0	3
38	APPLICATION OF HIGUCHI'S ALGORITHM IN CENTRAL BLOOD PRESSURE PULSE WAVES AND ITS POTENTIAL ASSOCIATION WITH HEMODYNAMIC PARAMETERS IN HYPERTENSIVE PATIENTS. Journal of Hypertension, 2019, 37, e234.	0.3	2
39	Hypertension and metabolic disorders, a glance from different phenotypes. American Journal of Preventive Cardiology, 2020, 2, 100032.	1.3	2
40	Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project. European Cardiology Review, 2021, 16, e16.	0.7	2
41	Medium to Long Term Follow-Up of Treated Hypertensive Mediated Heart Disease. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 383-391.	1.0	2
42	Ventricular-Arterial Uncoupling and Hypertension Mediated Diastolic Dysfunction. High Blood Pressure and Cardiovascular Prevention, 2022, , 1.	1.0	2
43	Effects of activation of vitamin D receptor and phosphorus on left ventricular hypertrophy in chronic kidney disease. Hipertension Y Riesgo Vascular, 2012, 29, 130-135.	0.3	1
44	World Health Organization cardiovascular risk stratification and target organ damage. Hipertension Y Riesgo Vascular, 2016, 33, 14-20.	0.3	1
45	Longitudinal left ventricular contractility in young isolated systolic hypertensives. Hipertension Y Riesgo Vascular, 2017, 34, 96-97.	0.3	1
46	National study on compliance to treatment. American Journal of Hypertension, 2005, 18, A88-A88.	1.0	0
47	ASSOCIATED FACTORS TO INADEQUATE CONTROL OF ARTERIAL BLOOD PRESSURE IN HYPERTENSIVE PATIENTS UNDER MEDICAL TREATMENT: CLINICAL PRACTICE BASED STUDY IN ARGENTINA. Journal of Hypertension, 2011, 29, e433-e434.	0.3	0
48	Presión arterial y daño en órgano blanco, diferencias entre las poblaciones urbana y rural de España. Hipertension Y Riesgo Vascular, 2014, 31, 79-82.	0.3	0
49	PP.18.09. Journal of Hypertension, 2015, 33, e293.	0.3	0
50	PP.02.20. Journal of Hypertension, 2015, 33, e144-e145.	0.3	0
51	[PP.33.14] TEI INDEX AS A TOOL FOR THE DIAGNOSIS OF LEFT VENTRICULAR DYSFUNCTION WITH PRESERVED EJECTION FRACTION IN HYPERTENSIVE PATIENTS. Journal of Hypertension, 2016, 34, e327-e328.	0.3	0
52	[PP.20.17] MORPHOLOGICAL EXPRESSION OF HYPERTENSION IN THE LEFT VENTRICULAR MYOCARDIUM. ANALYSIS OF FRACTAL DIMENSION BY ECHOCARDIOGRAPHY. Journal of Hypertension, 2016, 34, e244.	0.3	0
53	[PP.33.08] LONGITUDINAL LEFT VENTRICULAR CONTRACTILITY AND ISOLATED SYSTOLIC HYPERTENSION IN THE YOUNG. Journal of Hypertension, 2016, 34, e326.	0.3	0
54	PS 17-32 VARIABLES ASSOCIATED TO LACK OF LEFT VENTRICULAR HYPERTROPHY REGRESSION IN TREATED HYPERTENSIVE PATIENTS. Journal of Hypertension, 2016, 34, e482-e483.	0.3	0

#	ARTICLE	IF	CITATIONS
55	PS 17-67 VARIABLES ASSOCIATED TO LEFT VENTRICULAR HYPERTROPHY DEVELOPMENT IN TREATED HYPERTENSIVE PATIENTS. <i>Journal of Hypertension</i> , 2016, 34, e493.	0.3	0
56	Ethnicity and Left Ventricular Hypertrophy: Tools and Uncertainties. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 291-294.	1.0	0
57	Position statement on use of pharmacological combinations in a single pill for treatment of hypertension by Argentine Federation of Cardiology (FAC) and Argentine Society of Hypertension (SAHA). <i>Journal of Human Hypertension</i> , 2021, , .	1.0	0
58	SYSTOLIC BLOOD PRESSURE IS THE CLINICAL VARIABLE THAT BETTER CORRELATES WITH LEFT VENTRICLE MAS. <i>Journal of Hypertension</i> , 2004, 22, S156.	0.3	0
59	HEART RATE VARIABILITY AND LEFT VENTRICLE HYPERTROPHY. <i>Journal of Hypertension</i> , 2004, 22, S154.	0.3	0